Lilly Endowment Sells $62.3M in Eli Lilly (LLY) Stock
ELI LILLY & Co
Subscribe to track LLY
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Lilly Endowment Sells $62.3M in Eli Lilly (LLY) Stock
Company: ELI LILLY & Co (LLY) Form: 4 | Filed: 2025-11-19 Significance: Low
Insider: LILLY ENDOWMENT INC Relationship: Ten Percent Owner
Transaction: • Type: Sell • Shares: 60,213 • Avg. Price: $1,034.82 • Value: $62,309,615 • Owned After: 92,811,978
Key Insight: Despite the large dollar value, this sale represents a minuscule fraction (<0.1%) of the Endowment's total holdings and is immaterial relative to Eli Lilly's mega-cap status.
Market Context: Such sales by large foundations are often for liquidity or diversification and are not typically indicative of a change in outlook on the company.
Comprehensive Analysis
SEC Filing Analysis: ELI LILLY & Co (LLY)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Lilly Endowment Inc., a 10% owner, sold $62.3 million of Eli Lilly stock, a transaction that is insignificant relative to both its total holdings and the company's massive market capitalization.
- Market Impact: The sale is too small to have a material impact on the stock and is likely part of a routine diversification or liquidity strategy for the foundation.
Company Information
| Field | Value |
|---|---|
| Company | ELI LILLY & Co |
| Ticker Symbol | LLY |
| CIK | 0000059478 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | LILLY ENDOWMENT INC |
| CIK | 0000316011 |
| Title/Position | null |
| Relationship | Ten Percent Owner |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-18 |
| Transaction Code | S (Sale) |
| Security Type | Common Stock |
| Shares Involved | 60,213 |
| Price Per Share | $1,034.82 (Weighted Average) |
| Total Value | $62,309,615 |
| Shares Owned After | 92,811,978 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $62,309,615 |
| % of Market Cap | 0.0068% |
| Shares Transacted | 60,213 |
| % of Shares Outstanding | 0.0064% |
| Post-Transaction Ownership | 92,811,978 shares (9.81% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: For a mega-cap company with a market capitalization of $917.64 billion, a $62.3 million transaction is negligible and constitutes routine market activity.
- Ownership Concentration: The sale represents a tiny fraction (approximately 0.065%) of the Endowment's total stake in Eli Lilly. The insider continues to hold a substantial position of over 9.8% of all outstanding shares.
- Transaction Significance: The transaction's value and share count fall far below the thresholds for moderate or high significance (<0.1% of market cap and <0.1% of shares outstanding).
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The sale is immaterial in the context of the company's size and the insider's remaining position. It is unlikely to influence market sentiment or stock price.
Volume & Sentiment
- Expected Volume Impact: Minimal. The number of shares sold is a small fraction of the stock's typical daily trading volume.
- Sentiment Indicator: Neutral. This transaction is characteristic of a large foundation managing its portfolio for liquidity or diversification, not a bearish signal on the company's prospects.
Additional Context
Transaction Notes
- Special Circumstances: The filing reports ten separate transactions on the same day, which have been aggregated for this analysis. The sales were executed at weighted average prices, a common practice for large block trades to minimize market impact.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
